Article

Relationship Between Buprenorphine Adherence and Health Service Utilization and Costs Among Opioid Dependent Patients

Journal of substance abuse treatment (Impact Factor: 2.9). 11/2013; DOI: 10.1016/j.jsat.2013.10.014

ABSTRACT

Buprenorphine-medication assisted therapy (B-MAT) is an effective treatment for opioid dependence, but may be considered cost-prohibitive based on ingredient cost alone. The purpose of this study was to use medical and pharmacy claims data to estimate the healthcare service utilization and costs associated with B-MAT adherence among a sample of opioid dependent members. Members were placed into two adherence groups based on one-year medication possession ratio (≥ 0.80 vs. < 0.80). The B-MAT adherent group incurred significantly higher pharmacy charges (adjusted means; $6,156 vs. $3,581), but lower outpatient ($9,288 vs. $14,570), inpatient ($10,982 vs. $26,470), ER ($1,891 vs. $4,439), and total healthcare charges ($28,458 vs. $49,051; p < .01) compared to non-adherent members. Adherence effects were confirmed in general linear models. Though B-MAT adherence requires increased pharmacy utilization, adherent individuals were shown to use fewer expensive health care services, resulting in overall reduced healthcare expenditure compared to non-adherent patients.

Download full-text

Full-text

Available from: Joseph Tkacz, Mar 19, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Buprenorphine maintenance therapy (BMT) is increasingly the preferred opioid maintenance agent due to its reduced toxicity and availability in an office-based setting in the United States. Although BMT has been shown to be highly efficacious, it is often discontinued soon after initiation. No current systematic review has yet investigated providers’ or patients’ reasons for BMT discontinuation or the outcomes that follow. Hence, provider and patient perspectives associated with BMT discontinuation after a period of stable buprenorphine maintenance and the resultant outcomes were systematically reviewed with specific emphasis on pre-buprenorphine-taper parameters predictive of relapse following BMT discontinuation. Few identified studies address provider or patient perspectives associated with buprenorphine discontinuation. Within the studies reviewed providers with residency training in BMT were more likely to favor long term BMT instead of detoxification, and providers were likely to consider BMT discontinuation in the face of medication misuse. Patients often desired to remain on BMT because of fear of relapse to illicit opioid use if they were to discontinue BMT. The majority of patients who discontinued BMT did so involuntarily, often due to failure to follow strict program requirements, and 1 month following discontinuation, rates of relapse to illicit opioid use exceeded 50% in every study reviewed. Only lower buprenorphine maintenance dose, which may be a marker for attenuated addiction severity, predicted better outcomes across studies. Relaxed BMT program requirements and frequent counsel on the high probability of relapse if BMT is discontinued may improve retention in treatment and prevent the relapse to illicit opioid use that is likely to follow BMT discontinuation.
    Full-text · Article · Dec 2014 · Journal of Substance Abuse Treatment
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with opioid use disorders frequently discontinue opioid maintenance therapy (OMT) prematurely, reducing retention and possibly limiting the efficacy of OMT. The current study is a cross-sectional survey of patients (N=69) enrolled in buprenorphine maintenance therapy (BMT). We examined patient demographics, BMT characteristics (e.g., dose, time in BMT), and patient perspectives regarding intended duration of BMT. In addition, patients' reasons for continuing or discontinuing BMT were investigated. Results revealed that the majority (82%) of participants reported wanting to continue BMT for at least 12months. Age at first drug use, time in BMT, concern about pain, and concern about relapse were all positively associated with intended duration of BMT. The following were negatively associated with intended duration of BMT: recent discussion with a treatment provider about BMT discontinuation, prior attempt to discontinue BMT, concern about withdrawal symptoms, experiencing pleasurable effects from taking buprenorphine, and perceived conflicts of BMT with life, work, or school obligations. The most common reasons for wanting to continue BMT included concerns about withdrawal symptoms, relapse, and pain. Although preliminary, the findings highlight key issues with regard to patients' perspectives of BMT. The results of this study provide information that may be useful in improving OMT programs and treatment outcomes. Copyright © 2015. Published by Elsevier Inc.
    Full-text · Article · Apr 2015 · Journal of Substance Abuse Treatment
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: In the past ten years opioid maintenance treatment options for pregnancy have diversified, yet the incidence of neonatal abstinence syndrome (NAS) has increased. Aim: To compare NAS treatment outcomes in light of maternal treatment diversification of two cohorts treated in the same specialized facility monitored between 1999-2002 and 2009- 2012. Methods: Maternal and neonatal outcomes of 42 mother-neonate dyads monitored between 1999-2002 [n = 36 (86%) maintained on methadone (MET), mean daily dose at delivery 68.46 mg; n = 6 (14%) on buprenorphine (BUP), 8.80 mg/day] were compared with 68 opioid dependent mother-neonate dyads monitored between 2009-2012 [n = 39 (57.4%) maintained on MET, mean daily dose at delivery 58.62 mg; n = 29 (42.6%) on BUP, 9.60 mg/day] in terms of maternal demographic and treatment variables, birth outcome parameters and NAS outcomes. Results: The main finding was a reduction of pre-term birth rates (19% in the 1999-2002 cohort compared with 7% in the 2009-2012 cohort, p = 0.065) and the length of neonatal hospital stay (1999-2002: 27 days vs. 2009-2012: 18 days, p = 0.030). The average duration of gestation increased from 37.9 weeks (1999-2002) to 39.0 weeks (2009-2012) (p = 0.085). In addition, for methadone-maintained women, a significant reduction of concomitant substance use was shown over the investigated time frame. Conclusions: These results support the diversification of treatment options for pregnant opioid-dependent women in order to improve treatment efficacy for mother and child, with the potential to reduce the high costs of care in this population.
    No preview · Article · Dec 2015
Show more